http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102166982-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102166982-B1 |
| titleOfInvention | Correlation of CEACAM1 and EpCAM in liver cancer and Methods for providing information for liver cancer therapeutic effect using using the same |
| abstract | The present invention relates to a method for providing information on the correlation between CEACAM1 and EpCAM in liver cancer and the therapeutic effect of liver cancer using the same. In the present invention, it was confirmed that the expression of CEACAM1 in Huh7-EpCAM high cells had a positive correlation. In addition, since it was confirmed that suppressing the expression of CEACAM1 in EpCAM high liver cancer stem cells increases cytotoxicity by NK cells, thereby effectively killing hepatocellular carcinoma cells, the present invention relates to the treatment of liver cancer through inhibition of CEACAM1 expression in EpCAM-expressing liver cancer patients. It is possible to effectively provide a pharmaceutical composition for preventing and treating liver cancer comprising NK cells treated with information providing method, CEACAM1 expression inhibitor and anti-CEACAM1 antibody. |
| priorityDate | 2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.